Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.30 2.15% 61.80 61.00 62.60 61.80 60.50 60.50 175,643 10:18:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -10.9 -6.6 - 107

Angle Share Discussion Threads

Showing 50876 to 50899 of 50900 messages
Chat Pages: 2036  2035  2034  2033  2032  2031  2030  2029  2028  2027  2026  2025  Older
DateSubjectAuthorDiscuss
13/12/2019
11:30
PI's coming back after the election result?Welcome!
fhmktg
13/12/2019
11:17
Sorry - I've been out of the loop for a bit and saw the article in the Times this morning which appears to relate to this trial: hxxps://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-using-a-blood-test-to-find-certain-gene-changes-and-decide-treatment-for-advanced-breast#undefined. Do we know if they use Parsortix?
toffeeman
11/12/2019
16:18
Missed it. Will catch it online no doubt
waterloo01
11/12/2019
15:57
That presentation was interesting - or at least the bits I could understand! Sounds promising with regards to Parsortix.
semper vigilans
09/12/2019
10:46
Bermuda. I added to my s/h after reading your post 1869. Thanks.
hashertu
08/12/2019
19:56
Here is one of her presentations from May 2018 https://angleplc.com/wp-content/uploads/ANGLE-Presentation-Sixth-International-Molecular-Diagnostics-Europe-conference-24may18.pdf
jelenko
08/12/2019
18:55
Indeed. Must have missed your post.
waterloo01
08/12/2019
18:50
Waterloo, Yep, posted about this in my 1869 but not sure I got the message across very well:) On the face of it you would think this plays right into the hands of CTC liquid biopsy developers but WDIK?
bermudashorts
08/12/2019
18:23
Not an issue with CTC's! hTtps://www.mskcc.org/blog/many-mutations-detected-liquid-biopsy-tests-do-not-come-cancer-cells-msk-study-finds To their great surprise, more than half of the mutations identified in the cfDNA of people with cancer came from white blood cells, not from the cancer. This is a problem since most commercially available liquid biopsy tests do not include white blood cell testing.
waterloo01
08/12/2019
09:11
This is interesting at the Diagnostics Innovation Summit in May 2020:- hTTps://www.dxinnovationsummit.com/enabling-technologies-for-liquid-biopsy-and-beyond Title : Luncheon Presentation: Advances in CTCs Isolation and Characterisation using the Epitope-Independent Parsortix System Presenter : Anne-Sophie Pailhes-Jimenez, R&D Group Leader, Cell Biology and Imaging – R&D, ANGLE Looks like there may be progress in the 'development of a proprietary Parsortix harvest chip and a sample-to-answer imaging solution inter alia to progress the Abbott partnership' as referenced at the time of the £18m fundraise.
miavoce
05/12/2019
09:35
Angle webinar 11 Dechttps://twitter.com/WorldCDx/status/1200689923684282371?s=20
morgank
05/12/2019
09:31
Book - that may have been good initially, but may close down deals with other companies over time. Not sure (discussions on here before) about whether the huge pharmas carry any more clout with the FDA, but I hope AGLs US presence gives a bit of cover from it being A UK company.
semper vigilans
05/12/2019
09:22
Well McCarthy has somehow pulled of a near miracle so let's hope you're right.
bermudashorts
05/12/2019
08:40
We need more than a new MM., news and very good news, Newland reminds me of McCarthy at Immupharma, very good at spin, and not so good on execution. And I’m not talking about Parsotix , more about generating value for shareholders. I still believe that had Abbott been interested in acquiring a stake in Angle, he should have taken up the initiative, Abbott would have added a lot of extra clout with the FDA!
bookbroker
02/12/2019
17:23
I see we have acquired a new market maker.
jelenko
02/12/2019
08:58
And what is the relevance to Angle of the above post Sunningdale?
bookbroker
02/12/2019
08:51
For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year. CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/ This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen. Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.
sunningdale1
02/12/2019
08:46
For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year. CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/ This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen. Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.
sunningdale1
01/12/2019
20:48
Having read through past and current job vacancies, at Angle, impressed by the team being built. Some posters have been excellent at seeking out information about Parsortix, which I am grateful for, that sometimes hasn't been released by Angle. I am not sure how widely Angle's activities are known by potential investors.
4legs
30/11/2019
10:07
Blimey the old capacitor has had a bit of a discharge.
escapetohome
29/11/2019
10:52
Thanks Bermuda.
semper vigilans
29/11/2019
09:40
Semper, Whilst CTCs can be used for diagnostic purposes and to predict and monitor the correct treatment for a patient, I can't see how they can be used to predict adverse events to any therapy.
bermudashorts
29/11/2019
09:06
The whole issue before the fda is whether, for metastatic breast cancer, Pasortix is accurate and reproducible enough to move from being purely an indicative research tool to a full blown clinical indicator, useable as a gold standard.That's why there has been such a slow but steady process, because there isn't such a test in the market.The market potential is huge because of the speed and potential massive saving for the insurance industry...oh and patients get faster more accurate and reliable treatment options.It's a game changer and the first to market gets an enormous boost.The approval process for other cancers and foetal cell testing becomes defined in fda terms as well.Nobel prizes come for the inventors of technologies such as this!
fhmktg
29/11/2019
07:00
Chemo is a bit like firing a shot gun into a forest. You hit some things you aim at but also lots of collateral. The whole point of personalised medicine is precision targeting and Parsortix help identify who and what to target.
waterloo01
Chat Pages: 2036  2035  2034  2033  2032  2031  2030  2029  2028  2027  2026  2025  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191215 21:02:13